• FDA approval for Bavencio combo in advanced RCC pharmatimes
    May 15, 2019
    The US Food and Drug Administration (FDA) has approved Merck's Bavencio (avelumab) plus Inlyta (axitinib) combination for patients with advanced renal cell carcinoma.
PharmaSources Customer Service